Skip to content
Open in App
arGEN X BV logo

arGEN X BV

web2

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment o...

Symbol · 0QW0
Company profile

About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Positive Phase 3 ADAPT OCULUS topline results

KEY STEP

argenx announced that Phase 3 ADAPT OCULUS met its primary endpoint in adults with ocular myasthenia gravis. The result supports the company’s planned supplemental Biologics License Application to the US FDA seeking to expand VYVGART into ocular MG.

Roadmap reference

FDA expands VYVGART label to all adult gMG serotypes

KEY STEP

On May 8, 2026, the US FDA approved expanded indications for VYVGART and VYVGART Hytrulo covering all adult patients with generalized myasthenia gravis, including AChR positive, MuSK positive, LRP4 positive and triple seronegative serotypes.

Roadmap reference

Positive Phase 3 ALKIVIA topline results in autoimmune myositis

KEY STEP

argenx announced on August 17, 2026 that Phase 3 ALKIVIA met its primary endpoint in the combined IMNM and dermatomyositis population. VYVGART Hytrulo produced a 15.4 point greater mean Total Improvement Score improvement than placebo at Week 52, with p=0.0011. The IMNM subgroup also met the endpoint independently, supporting planned regulatory discussions for expansion into autoimmune myositis.

Roadmap reference
People

Company team

ML

Mary Lynne Hedley

Member of Board Advisors

Company leadership profile.

TV

Timothy Van Hauwermeiren

Co-Founder & Non-Independent Non-Executive Chairman of the Board

Company leadership profile.

KM

Karen Massey

CEO & Executive Director

Company leadership profile.

AA

Anthony A. Rosenberg

Independent Vice Chairman

Company leadership profile.

Hd

Hans de Haard

Co-Founder & Member of Board Advisors

Company leadership profile.

AC

Ana Cespedes

Independent Non-Executive Director

Company leadership profile.

SE

Steve Edward Krognes

Independent Non-Executive Director

Company leadership profile.

DL

David L. Lacey

Member of Board Advisors

Company leadership profile.

PM

Pamela M. Klein

Independent Non-Executive Director

Company leadership profile.

WP

Wim Parys

Member of Board Advisors

Company leadership profile.

CS

Camilla Sylvest

Independent Non-Executive Director

Company leadership profile.

BL

Brian L. Kotzin

Non-Executive Director

Company leadership profile.

Expert coverage

1 expert evaluated arGEN X BV.

Orbitrum research

Experts evaluating arGEN X BV

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment